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ABSTRACT 
Background 
Levodopa treatment in Parkinson’s disease (PD) causes motor fluctuations and dyskinesias, but few 
data describe their development or severity in unselected incident cohorts.  
 
Methods 
We gathered demographic, clinical, treatment, smoking, caffeine, and alcohol data from 183 people 
with PD from the PINE study, a community-based, incident cohort. With Kaplan-Meier survival 
analysis and Cox regression modelling we assessed the development, and severity, of dyskinesias 
and motor fluctuations and which factors independently influenced their onset. 
  
Results 
After mean follow-up of 59 months, 39 patients (21.3%) developed motor fluctuations and 52 
(28.4%) developed dyskinesias. Kaplan-Meier estimates of the probability of motor fluctuations and 
dyskinesias after 5 years of dopaminergic treatment were 29.2% (95% confidence interval [CI] 21.5–
38.8%) and 37.0% (95% CI 28.5–47.1%) respectively. 19.8% developed motor fluctuations requiring 
treatment changes but only 4.0% (95% CI 1.5–10.4%) developed dyskinesias requiring treatment 
changes by five years. Cumulative levodopa dose (Hazard ratio [HR] 1.38 [95% CI 1.19–1.60]), female 
sex (HR 2.41 [1.19–4.89]), and younger age at diagnosis (HR 1.08 [1.04–1.11]) were independently 
associated with development of motor fluctuations. Cumulative levodopa dose (HR 1.23 [1.08–
1.40]), female sex (HR 2.51 [1.40–4.51]) were independently associated with dyskinesias. In 
exploratory analyses, moderate caffeine exposure was associated with fewer motor fluctuations, 
longer symptom duration with more dyskinesias, and tremor at diagnosis with higher rates of both 
complications.  
 
Conclusions 
In this community-based incident PD cohort, severe dyskinesias were rare. Cumulative levodopa 
dose was the strongest predictor of both dyskinesias and motor fluctuations.
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INTRODUCTION 
Treatment of Parkinson’s disease (PD), especially with levodopa, causes dyskinesias and motor 
fluctuations. These motor complications are potentially disabling and may adversely affect patients’ 
quality of life.1-3 A previous review of studies of motor complications estimated that the risk of 
developing motor fluctuations and dyskinesias were both about 40% after levodopa treatment for 4-
6 years.4 However, most previous studies have been based on unrepresentative samples, with 
attendant selection biases, such as cohorts from specialist clinics or clinical trials in which younger 
patients with fewer co-morbidities than the general PD population are often over-represented.5,6 
Only two representative, community-based incidence studies have examined the development of 
motor complications over time, both of which were small, only reported dyskinesias7,8 and one was 
retrospective.8  
 
Several risk factors for the development of dyskinesias have been identified, including: younger age 
at diagnosis, female sex, higher levodopa dose, longer duration of levodopa therapy, and lower body 
weight,8-14 but most data come from non-incident or hospital-based studies. By contrast, few 
predictors of motor fluctuations have been identified but dose and duration on levodopa therapy 
are most commonly reported.12,15-18 In addition, nicotine, caffeine and alcohol may protect against 
the development of PD19 and there is some inconsistent clinical trial data to suggest caffeine and 
another adenosine A2A antagonist, may reduce dyskinesia risk.20,21  
 
We therefore aimed to (i) describe the development of dyskinesias and motor fluctuations in a 
prospective, community-based, incident cohort of PD; (ii) assess what factors influence their 
development; and (iii) describe the development of severe motor complications.  
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METHODS 
Study Design and Participants 
We used data from the Parkinsonism Incidence in North-East Scotland (PINE) study, a community-
based incidence study of PD and other parkinsonian disorders in Aberdeen and surrounding areas 
with prospective long-term follow-up.22,23 Attempts were made to identify all newly diagnosed 
patients with degenerative or vascular parkinsonism between 2002 and 2004 (pilot phase) and 2006 
to 2009 (main study phase) using multiple, overlapping methods for case ascertainment.23 All 
patients were asked to consent to long-term annual follow-up with interim appointments as 
required for clinical management. The study was approved by the Multi-centre Research Ethics 
Committee for Scotland and conducted with the informed consent of the patients involved. 
 
This analysis was restricted to patients who had a diagnosis of idiopathic PD at death or latest 
follow-up, made by a consultant neurologist with an interest in movement disorders (CEC) using the 
UK Brain Bank criteria,24 insofar as follow-up duration permitted supportive criteria to be applied. 
15% of patients with a latest diagnosis of PD had initially had an alternative diagnosis. Patients were 
excluded if they were not followed-up after baseline or if they had not received dopaminergic 
treatment. Patients were treated according to the clinical judgement of the treating clinicians.  
 
Data collection and assessment of motor complications 
At the baseline (i.e. diagnostic) assessment and at subsequent follow-up appointments, consenting 
patients were interviewed and examined, and information gathered included patient demographics 
and clinical characteristics (including the Unified PD Rating Scale [UPDRS]) and details of 
parkinsonian medication. Data were also gathered on exposure to caffeine, alcohol and smoking at 
verbal interview, including age at first exposure, average level of exposure before baseline and, if 
relevant, year exposure stopped. At each annual assessment, patients were asked about their 
ongoing exposures. 
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Data on motor complications were gathered from the prospectively acquired records of the 
examining study physician and from part IV of the UPDRS. In patients who reported motor 
complications, the month and year of onset were recorded from patient self-report or, in the case of 
asymptomatic dyskinesias that were seen at the assessment, the date of that assessment. 
Dyskinesias did not have to be witnessed by a physician to be included, but if they were not seen 
and the history was doubtful, they were not included. Severe motor complications were defined as 
those which required changes to parkinsonian treatment after discussion with the patient about 
their impact.   
 
Analysis 
The data were extracted from the PINE database (26th June, 2013), checked and cleaned. The 
cumulative levodopa only dose and the total levodopa-equivalent dose (LED)25 (including any 
dopamine replacement therapy) were calculated up to four years from diagnosis since almost all 
surviving patients had been followed-up for four years. Levodopa and levodopa-equivalent doses 
were calculated as levodopa or levodopa-equivalent dose in milligrams multiplied by number of days 
of treatment and divided by 105 to give units equivalent to about 70mg levodopa, on average, a day 
for 4 years. Cumulative alcohol and caffeine lifetime exposure were divided into tertiles and smoking 
exposure was categorised as never, low and high because there were large numbers of non-smokers 
in our cohort. Cups of tea and coffee were assumed to contain 47mg and 62mg of caffeine 
respectively.26 Tertiles of cumulative alcohol and caffeine exposure over three years after diagnosis 
were also calculated to investigate whether ongoing exposure after diagnosis was associated with 
fewer motor complications.  
 
We performed Kaplan-Meier survival analysis of motor fluctuation-free and dyskinesia-free survival 
from the start of any dopamine replacement therapy (levodopa, dopamine agonist, MAO-B inhibitor) 
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with patients censored at death or last follow-up. Survival analyses were also performed with 
different time baselines to facilitate comparisons with previous studies: i) levodopa initiation; and ii) 
diagnosis. Cox proportional hazards modelling was performed to assess what factors independently 
influenced the development of motor complications (using start of dopaminergic treatment as the 
baseline for survival). Univariable (unadjusted) hazards ratios were firstly calculated for all the 
variables listed in table 1. There were too many variables to include all in a multivariable model. On 
the basis of a priori evidence we selected four variables to include (irrespective of statistical 
significance) in the two main Cox regression models (i.e. one predicting motor fluctuations and one 
dyskinesias): age at diagnosis, sex, motor UPDRS score at baseline and cumulative levodopa dose up 
to four years from diagnosis. This ensured no fewer than about 10 events per variable in the main 
models.27 Additional exploratory analyses were performed to investigate the role of other variables 
including symptom duration prior to diagnosis, weight, MMSE score at diagnosis, different treatment 
measures (cumulative levodopa-equivalent dose, starting levodopa within one year of diagnosis) and 
measures of smoking, alcohol and caffeine exposure. These secondary analyses were performed by 
creating models with the four pre-specified variables together with each of the additional variables 
in turn. There were no missing data in the variables used in the main analysis; in the secondary 
analysis, if missing data were present for a particular variable, these observations were excluded 
from analyses including that variable. Statistical analyses were performed using SPSS version 21 and 
Stata version 12. 
 
 
RESULTS 
206 patients with a diagnosis of idiopathic PD at latest follow-up were identified from the PINE 
database (Figure 1), of which seven declined clinical follow-up, ten died before their first follow-up 
and six had not received dopaminergic medication by time of data extraction. These patients (mean 
age 70.8) were not treated because they had mild disease with tremor dominance (N=3), had early 
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dementia while motor symptoms were still mild (N=1), refused treatment (N=1), or did not tolerate 
levodopa (N=1). The remaining 183 treated idiopathic PD patients (57.4% male, mean age at 
diagnosis 71.7 years) were included in the main analyses. The mean duration of follow-up was 59 
months (SD 22). 66 patients (36.1%) died during the follow-up. Five patients (2.7%) were lost to 
clinical follow-up. 128 patients (69.9%) started levodopa within the first year of follow up (median 
duration to treatment onset 4 months, IQR 0-14 months). Most patients (69.9%) received levodopa 
in the first year after diagnosis and a further 24 (13.1%) received levodopa within four years of 
follow-up. The patients who received dopaminergic therapy in the first four years, but not levodopa, 
were mostly treated with ropinirole (33 patients), pramipexole (17 patients), selegiline (13 patients), 
COMT inhibitors (2 patients), rasagiline (1 patient), or ergot-derived dopamine agonists (2 patients). 
 
Motor Fluctuations 
Motor fluctuations occurred in 39 patients (21.3%) (see table 1 and figure 2A). The majority of these 
were severe enough to require changes in therapy (25 patients [13.7% of total participants, 64.1% of 
those with motor fluctuations]). These changes were mostly increased frequency of levodopa 
dosage or adding controlled release levodopa at night. Kaplan-Meier estimates of probability of 
developing motor fluctuations at five years, with different baselines for time measurement, are 
shown in table 3. The factors independently associated with the development of motor fluctuations 
in the main multivariable model were higher cumulative levodopa dose, female sex, and younger 
age at diagnosis (Table 1). In secondary analyses the presence of tremor at diagnosis was associated 
with a higher rate and moderate (though not high) lifetime caffeine intake was associated with a 
lower rate of motor fluctuations.  
 
Table 1. Characteristics of patients who developed motor fluctuations 
 
Characteristics 
 
Patients with 
fluctuations  
Patients 
without 
Unadjusted HR  
(95% CI) 
Adjusted HR* 
(95% CI) 
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N=39 fluctuations 
N=144 
Age at diagnosis in years, median (IQR) 71 (64-74) 74 (69-80) 0.97 (0.94-0.99) 0.93 (0.90-0.97) 
Sex: Female, N (%) 23 (59.0%) 55 (38.2%) 1.80 (0.95-3.40) 2.41 (1.19-4.89) 
Weight at diagnosis in kg, median (IQR) 70 (64-84) 73 (62-83) 1.00 (0.98-1.03) 1.02 (0.99-1.05) 
Motor UPDRS at diagnosis, median (IQR) 26 (18-36) 24 (15-32) 1.02 (0.99-1.05) 1.00 (0.96-1.03) 
MMSE at diagnosis, median (IQR) 
(N=14 missing) 
29 (28-30) 29 (27-29) 1.17 (0.97-1.42) 1.13 (0.90-1.42) 
Tremor at diagnosis, N (%) 37 (95.0%) 123 (85.4%) 3.50 (0.84-14.58) 4.80 (1.12-20.72) 
Duration between symptom onset and diagnosis in 
years, median (IQR) 
1.17 (0.83—2.00) 1.17 (0.75-2.06) 0.93 (0.75-1.14) 0.89 (0.71-1.13) 
Started on Levodopa within 1 year from diagnosis, N 
(%) 
25 (64.1%) 103 (71.5%) 0.91 (0.47-1.76) 0.75 (0.29-1.92) 
Cumulative Levodopa dose 4 years from diagnosis, 
median (IQR) 
5.56 (1.40-7.60) 2.56 (0.63-4.38) 1.16 (1.04-1.30) 1.38 (1.19-1.60) 
Cumulative LED 4 years from diagnosis, median (IQR) 6.43 (3.37-7.60) 3.28 (1.88-5.08) 1.24 (1.08-1.46) 1.01 (0.76-1.36) 
PD Subtype, N (%)     
 PIGD 17 (43.6%) 75 (52.1%) 1 1 
Intermediate 6 (15.4%) 20 (13.9%) 1.33 (0.53-3.38) 2.00 (0.73-5.44) 
 Tremor dominant 16 (41.0%) 49 (34.0%) 1.31 (0.66-2.60) 1.59 (0.78-3.28) 
Smoking lifetime exposure, N (%)     
Pack years [cigarettes per 
day / 20 x number of years 
of exposure] 
Never 27 (69.2%) 78 (54.2%) 1 1 
Low (1-18) 6 (15.4%) 37 (47.4%) 0.59 (0.24-1.43) 0.79 (0.32-1.94) 
High (>18) 6 (15.4%) 29 (20.1%) 0.65 (0.27-1.57) 0.74 (0.30-1.85) 
Current smokers at diagnosis, N (%) 4 (10.3%) 8 (5.5%) 1.70 (0.60-4.78) 1.40 (0.50-4.00) 
Alcohol lifetime exposure, N (%)     
[units of alcohol per 
week x years of 
exposure] 
Never/Low(<40) 16 (41.0%) 45 (31.3%) 1 1 
Moderate(40-240) 12 (30.8%) 49 (34.0%) 0.73 (0.35-1.56) 0.79 (0.35-1.77) 
High(>240) 11 (28.2%) 50 (34.7%) 0.63 (0.29-1.36) 0.71 (0.30-1.70) 
Alcohol 3 years after diagnosis, N (%)     
 Never/Low(<1) 14 (35.9%) 58 (40.3%) 1 1 
Moderate(1-11) 11 (28.2%) 38 (26.4%) 1.19 (0.54-2.62) 1.70 (0.73-3.97) 
High(>11) 14 (35.9%) 48 (33.3%) 1.18 (0.56-2.47) 1.70 (0.79-3.60) 
Caffeine lifetime exposure, N (%)     
[weight (in mg) per 
day x years of 
exposure] 
Never/Low(< 10,600) 17 (43.6%) 44 (30.6%) 1 1 
Moderate (10,600 - 16,400) 13 (33.3%) 48 (33.3%) 0.53 (0.26-1.10) 0.34 (0.15-0.76) 
High (>16,400) 9 (23.1%) 52 (36.1%) 0.50 (0.22-1.12) 0.57 (0.24-1.40) 
Caffeine 3 years after diagnosis, N (%)     
 Never/Low (<513) 8 (20.5%) 53 (36.8%) 1 1 
Moderate(513-744) 18 (46.2%) 42 (29.2%) 1.59 (0.68-3.72) 1.58 (0.62-4.06) 
High(>744) 13 (33.3%) 49 (34.0%) 1.10 (0.46-2.67) 1.12 (0.44-2.89) 
*Variables adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS at 
diagnosis, and cumulative levodopa dose 4). Abbreviation: PIGD= postural instability and gait disorder.  
 
Dyskinesias 
52 patients (28.4%) developed dyskinesias (see table 2 and figure 2B). At onset, only three patients 
(1.6% of total participants, 5.8% of those with dyskinesia) rated their dyskinesias as painful and five 
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(2.7% of total participants, 9.6% of those with dyskinesia) as mildly disabling; the rest were not 
disabling. Only 8 patients (4.4% of total participants, 15.4% of those with dyskinesia) developed 
dyskinesias which required treatment changes (such as decrease of levodopa dose or addition of 
amantadine). The median dyskinesia-free survival time was 85 months. Kaplan-Meier estimates of 
the probability of developing dyskinesias after five years, with different baselines for time 
measurement, are shown in table 3. Higher cumulative levodopa dose and female sex were found to 
be independent risk factors for the development of dyskinesias in the main model (Table 2). In the 
additional models, symptom duration and the presence of tremor at diagnosis were associated with 
more dyskinesias and there was a suggestion that higher MMSE score was associated with increased 
risk. 
 
Table 2. Characteristics of patients who developed dyskinesias 
Characteristics 
 
Patients with 
dyskinesias  
N=52 
Patients without 
dyskinesias  
N=131 
Unadjusted HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
Age at diagnosis in years, median (IQR) 73 (70-78) 73 (65-80) 1.02 (0.99-1.05) 1.00 (0.97-1.03) 
Sex: Female, N (%) 29 (55.8%) 49 (37.4%) 1.79 (1.03-3.10) 2.51 (1.40-4.51) 
Weight at diagnosis in Kg, median (IQR) 67 (60-75) 75 (64-85) 0.97 (0.96-0.99) 0.99 (0.96-1.01) 
Motor UPDRS at diagnosis, median (IQR) 29 (19-37) 23 (15-32) 1.03 (1.01-1.06) 1.01 (0.98-1.04) 
MMSE at diagnosis, median (IQR) 
(N=14 missing) 
29 (28-29) 29 (27-29) 1.07 (0.94-1.23) 1.17 (1.00-1.36) 
Tremor at diagnosis, N (%) 49 (94.2%) 111 (84.7%) 2.82 (0.88-9.07) 3.68 (1.14-11.90) 
Duration between symptom onset and diagnosis 
in years, median (IQR) 
1.21 (0.71-2.15) 1.08 (0.75-2.00) 1.19 (1.05-1.35) 1.02 (1.01-1.03) 
Started on Levodopa within 1 year from 
diagnosis, N (%) 
41 (78.8%) 87 (66.4%) 2.20 (1.13-4.30) 1.55 (0.65-3.70) 
Cumulative Levodopa dose 4 years from 
diagnosis, median (IQR) 
4.48 (2.34-6.90) 2.37 (0.23-4.07) 1.19 (1.08-1.32) 1.23 (1.08-1.40) 
Cumulative LED 4 years from diagnosis, median 
(IQR) 
5.87 (3.06-7.10) 3.28 (1.73-4.99) 1.19 (1.06-1.35) 1.00 (0.75-1.30) 
PD Subtype, N (%)     
 PIGD 26 (50.0%) 66 (50.4%) 1 1 
Intermediate 6 (11.5%) 20 (15.3%) 0.76 (0.31-1.85) 1.23 (0.50-3.10) 
Tremor dominant 20 (38.5%) 45 (34.3%) 0.96 (0.54-1.73) 1.64 (0.86-3.12) 
Smoking lifetime exposure, N (%)     
Pack years [cigarettes 
per day / 20 x number 
of years of exposure] 
Never 30 (57.7%) 75 (57.3%) 1 1 
Low (1-18) 10 19.2%) 33 (25.2%) 0.95 (0.46-1.95) 1.08 (0.52-2.23) 
High (>18) 12 (23.1%) 23 (17.6%) 1.40 (0.71-2.73) 1.21 (0.60-2.44) 
Current smokers at diagnosis, N (%) 4 (8.0%) 8 (6.1%) 0.85 (0.30-2.37) 0.80 (0.30-2.30) 
Alcohol lifetime exposure, N (%)     
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[units of alcohol per 
week x years of 
exposure] 
Never/Low(<40) 22 (42.3%) 39 (29.8%) 1 1 
Moderate(40-240) 14 (26.9%) 47 (35.9%) 0.53 (0.27-1.04) 0.63 (0.31-1.30) 
High(>240) 16 (30.8%) 45 (34.4%) 0.66 (0.35-1.30) 0.80 (0.38-1.68) 
Alcohol 3 years after diagnosis, N (%)     
 Never/Low(<1) 21 (40.4%) 51 (38.9%) 1 1 
Moderate(1-11) 11 (21.2%) 38 (29.0%) 0.67 (0.32-1.39) 0.90 (0.42-1.92) 
High(>11) 20 (38.5%) 42 (32.1%) 1.09 (0.59-2.01) 1.63 (0.85-3.14) 
Caffeine lifetime exposure, N (%)     
[weight (in mg) per 
day x years of 
exposure] 
Never/Low(< 10,600) 16 (30.7%) 45 (34.4%) 1 1 
Moderate (10,600 - 
16,400) 
20 (38.5%) 41 (31.3%) 1.26 (0.65-2.43) 0.81 (0.40-1.64) 
High (>16,400) 16 (30.7%) 45 (34.4%) 1.13 (0.56-2.25) 0.80 (0.38-1.67) 
Caffeine 3 years after diagnosis, N (%)     
 Never/Low (<513) 11 (21.2%) 50 (38.2%) 1 1 
Moderate(513-744) 20 (38.5%) 40 (30.5%) 1.56 (0.74-3.29) 1.40 (0.64-3.08) 
High(>744) 21 (40.4%) 41 (31.3%) 1.56 (0.75-3.24) 1.37 (0.65-2.87) 
*Variables are adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS 
at diagnosis, and cumulative levodopa dose). Abbreviation: PIGD= postural instability and gait disorder.  
 
Table 3: Kaplan-Meier probabilities of developing motor fluctuations and dyskinesias after 
five years from dopaminergic treatment initiation, from levodopa initiation, and from 
diagnosis. 
Baseline for time measurement  Motor fluctuations  
 
Dyskinesias 
Any complication 
     Starting dopaminergic treatment (N=183) 29.2% (21.5–38.8) 37.0% (28.5–47.1) 
     Starting levodopa treatment (N=160) 30.6% (22.6–40.7) 43.6% (33.7–54.9) 
     Diagnosis (N=189) 22.8% (16.7–30.7) 29.6% (22.7–37.8) 
Severe complications 
     Starting dopaminergic treatment (N=183) 19.8% (13.4–28.8) 4.0% (1.5–10.4) 
95% confidence intervals are in parentheses. 
 
 
Motor fluctuations and dyskinesias 
23 patients (12.6%) developed both fluctuations and dyskinesias, of whom 14 had developed 
dyskinesias first. 
 
 
DISCUSSION 
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About 30% of patients with PD developed motor fluctuations and about 37% developed dyskinesias 
within five years of starting dopaminergic treatment. These were higher risks than described in two 
other community-based incidence cohorts that examined the development of dyskinesias. A Mayo 
Clinic series reported that 30% of patients developed dyskinesias by five years of starting levodopa8 
and in another study fewer than 20% of patients developed dyskinesias five years from diagnosis.7 
The reasons for these differences, between similar studies, are unclear. No previous community-
based inception studies have reported the frequency of motor fluctuations. We found complications 
to be less common than several other studies, some of which were older and therefore used higher 
levodopa doses than are used in current practice.4,18 Dyskinesias were more common in our cohort 
than motor fluctuations, similar to some studies15,28 but not others.16,12,18 Disabling dyskinesias were 
rare and, although most patients with motor fluctuations did need changes in treatment, very few 
(4%) developed dyskinesias necessitating treatment changes. This is lower than one previous 
incident study in which 17% of patients required treatment changes for dyskinesias within five years 
of levodopa initiation.8 That study used patient records between 1976 and 1990 and the lower 
incidence of severe dyskinesias in our study, could be due to lower levodopa doses used in more 
recent prescribing practice. 
 
Levodopa exposure has consistently been reported as the strongest risk factor for the development 
of motor fluctuations and dyskinesias in observational studies,4,8,16 randomised trials of levodopa 
versus dopamine agonists29,30 and randomised trials of different levodopa doses.31 Previous studies 
have investigated several measures of levodopa exposure, including the initial average daily dose;7 
average daily LED;8 or levodopa dose at onset of dyskinesias (or study end in those without 
dyskinesias).12 Here we have compared cumulative both levodopa only and levodopa-equivalent 
doses up to four years and early (within one year of diagnosis) commencement of levodopa. 
Although these variables were correlated, only cumulative levodopa dose was significantly 
associated with motor complications when they were entered into a multivariable model together. 
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This suggests that there is little additional effect of non-levodopa dopaminergic treatments, similar 
to findings from a recent meta-analysis.32 It also suggests there is no absolute requirement to avoid 
early levodopa treatment in PD but, as others have suggested,12 it is important to use the smallest 
dose that adequately controls the patient’s symptoms throughout the course of PD. The fact that 
baseline motor severity (UPDRS) was not an independent risk factor for motor complications 
suggests that the association between cumulative levodopa dose and motor complications is not just 
due to worse disease severity with greater dopaminergic neuronal loss in those needing more 
levodopa. This conflicts with one large trial which found that both baseline disease severity and 
levodopa doses were associated with higher frequency of motor complications.12 However, evidence 
that levodopa increases risk of dyskinesias independently of disease severity also comes from 
randomised clinical trials, in which disease severity is randomly allocated to each arm, and those 
with higher doses of levodopa31 or levodopa and entacapone33 had higher incidence of dyskinesias. 
 
Many previous studies have shown that younger age at onset is associated with more dyskinesias,9,10 
and it was the most powerful predictor in a recent large trial.12 We found that age at diagnosis did 
not predict dyskinesias, similar to another community-based incidence study.7 It may be that, as a 
community-based incidence study, with proportionally few young-onset patients (4.4% under 50), 
there was insufficient power to detect an effect of age on dyskinesias.  
 
Duration between symptom onset and diagnosis was found to be an independent risk factor for 
developing dyskinesias but not motor fluctuations. This result was independent of baseline disease 
severity and levodopa dose so does not appear to be an effect of those presenting later being 
treated with higher doses of levodopa. This finding must be interpreted cautiously because it was a 
secondary analysis and the variable is subject to recall bias but it may suggest that patients with 
more indolent onset of their PD symptoms may be at a higher risk of developing dyskinesias. 
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The presence of tremor at diagnosis was associated with higher risk of both motor fluctuations and 
dyskinesias in the secondary analyses, which contrasts with a previous smaller study.34 Although 
consistent for both types of complications, the number without any tremor at baseline in this post-
hoc analysis was small so this finding, whilst novel and interesting, requires replication.  
 
Female gender was an independent risk factor for both motor fluctuations and dyskinesias, as 
previous studies have also shown.12 The reasons for gender differences in the development of motor 
complications are unclear. A possible explanation is that lower average weight in females results in 
higher levodopa doses per body weight, and some previous studies found lower weight was a risk 
factor for dyskinesias.35,36 We did not, however, demonstrate an association with baseline weight 
but changes in weight after diagnosis may be more important in the development of complications. 
It has also been suggested that females have a reduced genetic protection from a dopamine 
receptor polymorphism,11 and hormonal differences may be important, with evidence from animal 
models of effects of oestrogen on the basal ganglia.37  
 
Moderate lifetime caffeine exposure was associated with a reduced risk of developing motor 
fluctuations in the secondary multivariable analyses but there was no dose-response gradient and, 
given the large number of associations tested in the secondary analyses, it may well be a false 
positive. Nevertheless, a clinical trial showed caffeine lowered risk of dyskinesias20 and a trial of 
another adenosine A2A antagonist, istradefylline reduced daily OFF time.21 We did not find smoking 
or alcohol exposure, either before or after diagnosis to be associated with lower risk of dyskinesias. 
This is consistent with a previous study which showed smoking was not associated with motor 
complications.14 However, we lacked power to identify small effects of these exposures on motor 
complications.  
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The principal strengths of this study are its prospective design; the representative sample (attempts 
were made to identify all patients in the community with a new parkinsonian syndrome); regular 
reviewed of diagnoses to improve diagnostic accuracy; frequent (at least yearly) clinical review to 
obtain data on motor complications; very high study retention; and careful statistical analyses. 
Additionally, cumulative levodopa doses were calculated up to 4 years rather than at complication 
onset. This is clearly better than comparing levodopa dose at onset of motor complications with 
levodopa dose at end of study in those without complications as this is confounded by difference in 
time. 
 
The study has several limitations. Firstly, study size, while not small in terms of previous studies of 
motor complications, is insufficient to identify weak associations or investigate interactions. 
Secondly, average follow-up duration was only about five years, so better data may be obtained with 
longer follow-up. Thirdly, some inaccuracy in defining onset of complications is inevitable. Exact 
timing of onset of both dyskinesias and motor fluctuations was mostly subject to patient recall, 
although some patients’ dyskinesias were observed at clinic visits before they were noticed by the 
patients themselves, and were recorded as starting when seen. Thus the time to onset of dyskinesias 
may be overestimated. Assessment of severity was based on data about changes in therapy, which 
was derived from comprehensive clinical letter that invariably included reasons for treatment 
changes so we believe this was a reliable assessment. Fourthly, the secondary analyses must be 
considered as exploratory as many variables were examined and type I errors are possible. Fifthly, 
data on caffeine, smoking and alcohol were partly retrospective, only average exposures were used, 
and we did not gather data on sources of caffeine other than tea and coffee.  
 
In conclusion, we are the first to describe the development of both motor fluctuations and 
dyskinesias in a representative, community-based, incident cohort of PD. We estimate that 29% and 
37% develop motor fluctuations and dyskinesias respectively after 5 years of dopaminergic 
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treatment. Dyskinesias requiring treatment changes were rare (4% at 5 years), which is lower than 
previous estimates. Higher cumulative levodopa dose, female sex, and tremor at diagnosis were 
independent risk factors for both motor complications; moderate lifetime caffeine exposure and 
younger age for fewer motor fluctuations; and longer pre-diagnosis symptom duration for more 
dyskinesias. Further work with more patients with longer follow-up would be useful for more 
detailed analysis of risk factors. Individual-patient-data meta-analysis of existing representative 
studies would be an efficient way to do this.  
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FIGURE LEGENDS 
 
Figure 1. Flow chart of patients included in the analysis and initiation of levodopa treatment. FU: Follow-Up. 
*Patients received only dopamine agonist or MAO-B inhibitors within 4 years of follow-up, except for 5 
patients who received treatment after 4 years of follow-up.  
 
Figure 2. Kaplan-Meier estimates of the probability that PD patients on a dopaminergic therapy will be free 
from (A) motor fluctuations and (B) dyskinesias. In each graph, the blue line represents the development of 
any motor complication and the red represents the development of severe complications, i.e., those needing 
changes to treatment. 
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ABSTRACT 
Background 
Levodopa treatment in Parkinson’s disease (PD) causes motor fluctuations and dyskinesias, but few 
data describe their development or severity in unselected incident cohorts.  
 
Methods 
We gathered data on demographics, clinical details, drug treatment, and smoking, caffeine, and 
alcohol data history from 183 people with PD from the PINE study, a community-based, incident 
cohort. With Kaplan-Meier survival analysis and Cox regression modelling we assessed the 
development, and severity, of dyskinesias and motor fluctuations and which factors independently 
influenced their onset. 
  
Results 
After mean follow-up of 59 months, 39 patients (21.3%) developed motor fluctuations and 52 
(28.4%) developed dyskinesias after mean 59 months (SD). Kaplan-Meier estimates of the probability 
of motor fluctuations and dyskinesias after 5 years of dopaminergic treatment was were 29.2% (95% 
confidence interval [CI] 21.5–38.8%) and of dyskinesias was 37.0% (95% CI 28.5–47.1%) respectively. 
19.8% developed motor fluctuations requiring treatment changes but only 4.0% (95% CI 1.5–10.4%) 
developed dyskinesias requiring treatment changes by five years. Cumulative levodopa dose (Hazard 
ratio [HR] 1.38 [95% CI 1.19–1.60]), female sex (HR 2.41 [1.19–4.89]), and, and younger age at 
diagnosis (HR 1.08 [1.04–1.11])  were independently associated with development of motor 
fluctuations. Cumulative levodopa dose (HR 1.23 [1.08–1.40]), and female sex (HR 2.51 [1.40–4.51])  
were independently associated with dyskinesias. In secondary exploratory analyses, moderate 
caffeine exposure was associated with lower rates offewer motor fluctuations, longer symptom 
duration with more dyskinesias, and tremor at diagnosis with higher rates of both complications.  
 
Conclusions 
In this community-based incident PD cohort, severe dyskinesias were rare. Cumulative levodopa 
dose was the strongest predictor of both dyskinesias and motor fluctuations.
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INTRODUCTION 
Treatment of Parkinson’s disease (PD), especially with levodopa, is associated with the 
developmentcauses of motor complications, namely dyskinesias and motor fluctuations. These 
motor complications are common and potentially disabling consequences of chronic levodopa 
therapy and may adversely affect patients’ quality of life.1-3 
 
Ahlskog and Muenter reviewed A previous review of studies of dyskinesias and motor 
fluctuationscomplications and estimated that the risk of developing motor fluctuations and 
dyskinesias were both about 40% after levodopa treatment for 4-6 years.4 However, most previous 
studies have been based on unrepresentative samples, with attendant selection biases, such as 
cohorts derived from specialist clinics cohortsor clinical trials in which younger onset patients with 
fewer co-morbidities than the general PD population are often over-represented.5, or from clinical 
trials in which trial participants again tend to beare, on average, younger than the general PD 
population with fewer co-morbidities.6 Only two representative, community-based incidence studies 
have examined the development of motor complications over time, both of which were small, only 
reported dyskinesias7,8 and one was retrospective.8 The latter showed that whilst dyskinesias were 
common (30%) at five years, most were mild and only 17% required treatment adjustment.8 
 
Several risk factors for the development of dyskinesias have been identified, including: younger age 
at PD diagnosis, female sex, higher levodopa dose, longer duration of levodopa therapy, and lower 
body weight.,8-14 The two previous community-based incident cohorts both found that higher initial 
levodopa dose was an independent risk factor for developing dyskinesias, whereas only one8 found 
age at diagnosis to be an independent risk factorbut most data come from non-incident or hospital-
based studies. By contrast, relatively few data on predictors of motor fluctuations are availablehave 
been identified but dose and duration on levodopa therapy are most commonly reported.12,15-18 In 
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addition, cigarette smokingnicotine, caffeine and alcohol may protect against the development of 
PD19 and there is also some inconsistent clinical trial dataevidence from clinical trials to suggest that 
caffeine and another adenosine A2A antagonist, may reduce dyskinesiathe risk of developing motor 
complications.20,21  
 
We therefore aimed to (i) describe the development of dyskinesias and motor fluctuations in a 
prospective, community-based, incident cohort of treated PD; (ii) assess what factors influence their 
development; and (iii) describe the development of severe dyskinesias and motor 
fluctuationscomplications.  
 
 
METHODS 
Study Design and Participants 
We used data from the Parkinsonism Incidence in North-East Scotland (PINE) study, a community-
based incidence study of PD and other parkinsoniansm disorders in Aberdeen and surrounding areas 
with prospective long-term follow-up.22,23 Attempts were made to identify all newly diagnosed 
patients with degenerative or vascular parkinsonism between 2002 and 2004 (pilot phase) and 2006 
to 2009 (main study phase) using multiple, overlapping methods for case ascertainment.23 All 
patients were asked to consent to long-term annual follow-up with interim appointments as 
required for clinical management. The PINE study was approved by the Multi-centre Research Ethics 
Committee for Scotland and was conducted with the informed consent of the patients involved. 
 
This analysis was restricted to patients who had a diagnosis of idiopathic PD at death or latest 
follow-up, made by a consultant neurologist with an interest in movement disorders (CEC) using the 
UK Brain Bank criteria,24 insofar as follow-up duration permitted the supportive criteria to be 
applied. 15% of patients with a latest diagnosis of PD had initially had an alternative diagnosis. 
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Patients were excluded if they were not followed-up after baseline or if they had not received 
dopaminergic treatment. The study size was determined by the number of incident patients in the 
study period.  Treatment was initiated and managedPatients were treated according to the clinical 
judgement of the treating clinicians.  
 
Data collection and assessment of motor complications 
At the baseline (i.e. diagnostic) assessment and at subsequent follow-up appointments, consenting 
patients who had consented were interviewed and examined, and information gathered included 
patient demographics and clinical characteristics (including the Unified PD Rating Scale [UPDRS]) and 
detains of parkinsonian medication. Data were also gathered on exposure to caffeine, alcohol and 
smoking at verbal interview, including age at first exposure, average level of exposure before 
baseline and, if relevant, year exposure stopped. At each annual assessment, patients were asked 
about their ongoing exposures. 
 
Data on motor complications were gathered from the prospectively acquired records of the 
examining study physician and from part IV of the UPDRS. In patients who reported motor 
complications, the month and year of onset were recorded from patient self-report or, in the case of 
asymptomatic dyskinesias that were seen at the assessment, the date of that assessment.(which 
were based on clinical history and examination and included date of onset) and from part IV of the 
UPDRS. Dyskinesias did not have to be witnessed by a physician to be included, but if they were not 
seen and the history was doubtful, they were not included. Severe motor complications were 
defined as those which requireding changes to parkinsonianin treatment after discussion with the 
patient about their impact.   
 
Analysis 
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The data were extracted from the PINE database (26th June, 2013), checked and cleaned. Medication 
histories were updated each year, from which we calculated tThe cumulative levodopa only dose 
and the total levodopa-equivalent dose (LED)25 (including any dopamine replacement therapy) were 
calculated up to four years from diagnosis since almost all surviving patients had been followed-up 
for four years. Levodopa and levodopa-equivalent doses were calculated as levodopa or levodopa-
equivalent dose in milligrams multiplied by number of days of treatment and divided by 105 to give 
units equivalent to about 70mg levodopa, on average, a day for 4 years. Measures of cumulative 
lifetime exposure at baseline for caffeine, alcohol and smoking were calculated. Cumulative Aalcohol 
and caffeine lifetime exposure was were divided into tertiles and smoking exposure was categorised 
as never, low and high because there were large numbers of non-smokers in our cohort. Weight of 
caffeine was calculated on the basis of a cCups of tea and coffee were assumed to containing 47mg 
and 62mg of caffeine respectivelyand a cup of coffee containing 62mg.26 Measures Tertiles of 
cumulative alcohol and caffeine exposure to caffeine and alcohol over three years after diagnosis 
were also calculated to investigate whether ongoing exposure after diagnosis was associated with 
fewer motor complications and divided into tertiles; this was not calculated for smoking as there 
were too few current smokers in the study.  
 
We performed Kaplan-Meier survival analysis of motor fluctuation-free and dyskinesia-free survival 
from the start of any dopamine replacement therapy (levodopa, dopamine agonist, MAO-B inhibitor) 
with patients censored at death or last follow-up. Survival analyses were also performed with 
different time baselines to facilitate comparisons with previous studies: i) levodopa initiation; and ii) 
diagnosis. Cox proportional hazards modelling was performed to assess what factors independently 
influenced the development of motor complications from the onset of dopaminergic therapy (using 
start of dopaminergic treatment as the baseline for survival). Univariable (unadjusted) hazards ratios 
were firstly calculated for all the variables listed in table 1. There were too many variables to include 
all in a multivariable model. On the basis of a priori evidence we selected four variables to include 
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(irrespective of statistical significance) in the two main Cox regression models (i.e., one for the 
development of predicting motor fluctuations and one for dyskinesias): age at diagnosis, sex, motor 
UPDRS score at baseline and cumulative levodopa dose up to four years from diagnosis. This ensured 
that there was no fewer thatn about 10 events per variable in the main models.27 Additional 
exploratory analyses were performed to investigate the role of other variables including symptom 
duration prior to diagnosis, weight, MMSE score at diagnosis, different treatment measures of 
levodopa exposure (cumulative levodopa-equivalent dose, starting levodopa within one year of 
diagnosis) and measures of smoking, alcohol and caffeine exposure. These secondary analyses were 
performed by creating models with the four pre-specified variables together with each of the 
additional variables in turn. There were no missing data in the variables used in the main analysis; in 
the secondary analysis, if missing data were present for a particular variable, these observations were 
excluded from analyses including that variable. Statistical analyses were performed using SPSS 
version 21 and Stata version 12. 
 
 
RESULTS 
211206 patients with a diagnosis of idiopathic PD at latest follow-up were identified from the PINE 
database (Figure 1), of which 11 seven had declined clinical follow-up, a further ten had died before 
their first follow-up and eightsix had not received any dopaminergic medication by time of data 
extraction. These patients (mean age 70.8) were not treated because they had mild disease with 
tremor dominance (N=3), had early dementia while motor symptoms were still mild (N=1), refused 
treatment (N=1), or did not tolerate levodopa (N=1). The remaining 183 treated idiopathic PD 
patients (57.4% male, mean age at diagnosis 71.7 years) were included in the main analyses. The 
mean duration of follow-up was 59 months (SD 22). 66 patients (36.1%) died during the follow-up. 
Five patients (2.7%) were lost to clinical follow-up. 128 patients (69.9%) started levodopa within the 
first year of follow up (median duration to treatment onset 4 months, IQR 0-14 months). Most 
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patients (69.9%) received levodopa in the first year after diagnosis and a further 24 (13.1%) received 
levodopa within four years of follow-up. The patients who received dopaminergic therapy in the first 
four years, but not levodopa, were mostly treated with ropinirole (33 patients), pramipexole (17 
patients), selegiline (13 patients), COMT inhibitors (2 patients), rasagiline (1 patient), or ergot-
derived dopamine agonists (2 patients). 
 
Motor Fluctuations 
Motor fluctuations occurred in 39 patients (21.3%) by the time of data extraction (see table 1 and 
figure 2A). The majority of these were severe enough to require changes in therapy (25 patients 
[13.7% of total participants, 64.1% of those with motor fluctuations]). These changes were mostly 
increased frequency of levodopa dosage or adding a controlled release levodopa at night. Kaplan-
Meier estimates of probability of developing motor fluctuations at five years, with different 
baselines for time measurement, are shown in table 3. After five years on therapy the Kaplan-Meier 
estimate of the probability of developing any motor fluctuations was 29.2% (95% CI 21.5–38.8%) and 
of developing severe motor fluctuations was 19.8% (95% CI 13.4–28.8%) (Figure 2A). In the 160 
patients treated with levodopa,  probability of developing any motor fluctuation five years from 
levodopa initiation was 30.6% (95% CI 22.6–40.7%). In 191 patients (including eight untreated 
patients) the probability of developing motor fluctuations five years from diagnosis was 23.4% (95% 
CI 16.6–30.4%). The factors independently associated with the development of motor fluctuations in 
the main multivariable model were higher cumulative levodopa dose over the four follow-up years 
since baseline, female sex, and younger age at diagnosis (Table 1). In the secondary analyses the 
presence of tremor at diagnosis was associated with a higher rate and moderate (though not high) 
lifetime caffeine intake was associated with a lower rate of motor fluctuations. None of the other 
variables was significantly associated in multivariable analyses.  
 
Table 1. Characteristics of patients who developed motor fluctuations 
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Characteristics 
 
Patients with MF 
fluctuations  
N=39 
Patients 
without MF 
fluctuations 
N=144 
Unadjusted HR  
(95% CI) 
Adjusted HR*† 
(95% CI) 
Age at diagnosis in years, median (IQR) 71 (64-74) 74 (69-80) 0.97 (0.94-0.99) 0.93 (0.90-0.97) 
Sex: Female, N (%) 23 (59.0%) 55 (38.2%) 1.80 (0.95-3.40) 2.41 (1.19-4.89) 
Weight at diagnosis in kg, median (IQR) 70 (64-84) 73 (62-83) 1.00 (0.98-1.03) 1.02 (0.99-1.05) 
Motor UPDRS at diagnosis, median (IQR) 26 (18-36) 24 (15-32) 1.02 (0.99-1.05) 1.00 (0.96-1.03) 
MMSE at diagnosis, median (IQR) 
(N=14 missing) 
29 (28-30) 29 (27-29) 1.17 (0.97-1.42) 1.13 (0.90-1.42) 
Tremor at diagnosis, N (%) 37 (95.0%) 123 (85.4%) 3.50 (0.84-14.58) 4.80 (1.12-20.72) 
Duration between symptom onset and diagnosis in 
years, median (IQR) 
1.17 (0.83—2.00) 1.17 (0.75-2.06) 0.93 (0.75-1.14) 0.89 (0.71-1.13) 
Started on Levodopa within 1 year from diagnosis, N 
(%) 
25 (64.1%) 103 (71.5%) 0.91 (0.47-1.76) 0.75 (0.29-1.92) 
Cumulative Levodopa dose 4 years from diagnosis, 
median (IQR) 
5.56 (1.40-7.60) 2.56 (0.63-4.38) 1.16 (1.04-1.30) 1.38 (1.19-1.60) 
Cumulative LED* 4 years from diagnosis, median (IQR) 6.43 (3.37-7.60) 3.28 (1.88-5.08) 1.24 (1.08-1.46) 1.01 (0.76-1.36) 
PD Subtype, N (%)     
 PIGD 17 (43.6%) 75 (52.1%) 1 1 
Intermediate 6 (15.4%) 20 (13.9%) 1.33 (0.53-3.38) 2.00 (0.73-5.44) 
 Tremor dominant 16 (41.0%) 49 (34.0%) 1.31 (0.66-2.60) 1.59 (0.78-3.28) 
Smoking lifetime exposure, N (%)     
Pack years [cigarettes per 
day / 20 x number of years 
of exposure] 
Never 27 (69.2%) 78 (54.2%) 1 1 
Low (1-18) 6 (15.4%) 37 (47.4%) 0.59 (0.24-1.43) 0.79 (0.32-1.94) 
High (>18) 6 (15.4%) 29 (20.1%) 0.65 (0.27-1.57) 0.74 (0.30-1.85) 
Current smokers at diagnosis, N (%) 4 (10.3%) 8 (5.5%) 1.70 (0.60-4.78) 1.40 (0.50-4.00) 
Alcohol lifetime exposure, N (%)     
[units of alcohol per 
week x years of 
exposure] 
Never/Low(<40) 16 (41.0%) 45 (31.3%) 1 1 
Moderate(40-240) 12 (30.8%) 49 (34.0%) 0.73 (0.35-1.56) 0.79 (0.35-1.77) 
High(>240) 11 (28.2%) 50 (34.7%) 0.63 (0.29-1.36) 0.71 (0.30-1.70) 
Alcohol 3 years after diagnosis, N (%)     
 Never/Low(<1) 14 (35.9%) 58 (40.3%) 1 1 
Moderate(1-11) 11 (28.2%) 38 (26.4%) 1.19 (0.54-2.62) 1.70 (0.73-3.97) 
High(>11) 14 (35.9%) 48 (33.3%) 1.18 (0.56-2.47) 1.70 (0.79-3.60) 
Caffeine lifetime exposure, N (%)     
[weight (in mg) per 
day x years of 
exposure] 
Never/Low(< 10,600) 17 (43.6%) 44 (30.6%) 1 1 
Moderate (10,600 - 16,400) 13 (33.3%) 48 (33.3%) 0.53 (0.26-1.10) 0.34 (0.15-0.76) 
High (>16,400) 9 (23.1%) 52 (36.1%) 0.50 (0.22-1.12) 0.57 (0.24-1.40) 
Caffeine 3 years after diagnosis, N (%)     
 Never/Low (<513) 8 (20.5%) 53 (36.8%) 1 1 
Moderate(513-744) 18 (46.2%) 42 (29.2%) 1.59 (0.68-3.72) 1.58 (0.62-4.06) 
High(>744) 13 (33.3%) 49 (34.0%) 1.10 (0.46-2.67) 1.12 (0.44-2.89) 
*Cumulative levodopa-equivalent dose (LED) up to 4 years from diagnosis (mg lLevodopa-equivalent dose (mg) 
x number of days of treatment x 10
-5
; one unit is equivalentequals about to 70mg levodopa on average a day 
for 4 years). †Variables adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor 
UPDRS at diagnosis, and cCumulative lLevodopa dose 4 years from diagnosis). Abbreviations: HR=hazards ratio; 
IQR=interquartile range;; PIGD= postural instability and gait disorder; MF=motor fluctuations.  
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Dyskinesias 
52 patients (28.4%) had developed dyskinesias by the time of data extraction (see table 2 and figure 
2B). At onset, only three patients (1.6% of total participants, 5.8% of those with dyskinesia) rated 
their dyskinesias as painful and five (2.7% of total participants, 9.6% of those with dyskinesia) as 
mildly disabling; the rest were not disabling. Only 8 patients (4.4% of total participants, 15.4% of 
those with dyskinesia) developed dyskinesias which required treatment changes (such as decrease 
of levodopa dose or addition of amantadine). The median dyskinesia-free survival time  to onset of 
dyskinesias was 85 months. After five years on therapy the Kaplan-Meier estimates of the probability 
of developing dyskinesias after five years, with different baselines for time measurement, are shown 
in table 3. was 37.0% (95% CI 28.5–47.1%) and of developing severe dyskinesias was 4.0% (95% CI 
1.5–10.4%) (Figure 2B). The median time to onset of dyskinesias was 85 months. In the 160 patients 
treated with levodopa, probability of developing any dyskinesia five years from levodopa initiation 
was 43.6% (95% CI 33.7–54.9). In 191 patients (including eight untreated patients) the probability of 
developing dyskinesias five years from diagnosis was 29.3% (95% CI 22.5–37.6%). Higher cumulative 
levodopa dose at 4 years from diagnosis and, female sex were found to be independent risk factors 
for the development of dyskinesias in the main multivariable model (Table 2). In the additional 
models, symptom duration and the presence of tremor at diagnosis was were associated with higher 
rates ofmore dyskinesias and there was a suggestion that higher MMSE score was associated with 
increased risk. 
 
Table 2. Characteristics of patients who developed dyskinesias 
 
Characteristics 
 
Patients with 
dyskinesias  
N=52 
Patients without 
dyskinesias  
N=131 
Unadjusted HR 
(95% CI) 
Adjusted HR*† 
(95% CI) 
Age at diagnosis in years, median (IQR) 73 (70-78) 73 (65-80) 1.02 (0.99-1.05) 1.00 (0.97-1.03) 
Sex: Female, N (%) 29 (55.8%) 49 (37.4%) 1.79 (1.03-3.10) 2.51 (1.40-4.51) 
Weight at diagnosis in Kg, median (IQR) 67 (60-75) 75 (64-85) 0.97 (0.96-0.99) 0.99 (0.96-1.01) 
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Motor UPDRS at diagnosis, median (IQR) 29 (19-37) 23 (15-32) 1.03 (1.01-1.06) 1.01 (0.98-1.04) 
MMSE at diagnosis, median (IQR) 
(N=14 missing) 
29 (28-29) 29 (27-29) 1.07 (0.94-1.23) 1.17 (1.00-1.36) 
Tremor at diagnosis, N (%) 49 (94.2%) 111 (84.7%) 2.82 (0.88-9.07) 3.68 (1.14-11.90) 
Duration between symptom onset and diagnosis 
in years, median (IQR) 
1.21 (0.71-2.15) 1.08 (0.75-2.00) 1.19 (1.05-1.35) 1.02 (1.01-1.03) 
Started on Levodopa within 1 year from 
diagnosis, N (%) 
41 (78.8%) 87 (66.4%) 2.20 (1.13-4.30) 1.55 (0.65-3.70) 
Cumulative Levodopa dose 4 years from 
diagnosis, median (IQR) 
4.48 (2.34-6.90) 2.37 (0.23-4.07) 1.19 (1.08-1.32) 1.23 (1.08-1.40) 
Cumulative LED* 4 years from diagnosis, median 
(IQR) 
5.87 (3.06-7.10) 3.28 (1.73-4.99) 1.19 (1.06-1.35) 1.00 (0.75-1.30) 
PD Subtype, N (%)     
 PIGD 26 (50.0%) 66 (50.4%) 1 1 
Intermediate 6 (11.5%) 20 (15.3%) 0.76 (0.31-1.85) 1.23 (0.50-3.10) 
Tremor dominant 20 (38.5%) 45 (34.3%) 0.96 (0.54-1.73) 1.64 (0.86-3.12) 
Smoking lifetime exposure, N (%)     
Pack years [cigarettes 
per day / 20 x number 
of years of exposure] 
Never 30 (57.7%) 75 (57.3%) 1 1 
Low (1-18) 10 19.2%) 33 (25.2%) 0.95 (0.46-1.95) 1.08 (0.52-2.23) 
High (>18) 12 (23.1%) 23 (17.6%) 1.40 (0.71-2.73) 1.21 (0.60-2.44) 
Current smokers at diagnosis, N (%) 4 (8.0%) 8 (6.1%) 0.85 (0.30-2.37) 0.80 (0.30-2.30) 
Alcohol lifetime exposure, N (%)     
[units of alcohol per 
week x years of 
exposure] 
Never/Low(<40) 22 (42.3%) 39 (29.8%) 1 1 
Moderate(40-240) 14 (26.9%) 47 (35.9%) 0.53 (0.27-1.04) 0.63 (0.31-1.30) 
High(>240) 16 (30.8%) 45 (34.4%) 0.66 (0.35-1.30) 0.80 (0.38-1.68) 
Alcohol 3 years after diagnosis, N (%)     
 Never/Low(<1) 21 (40.4%) 51 (38.9%) 1 1 
Moderate(1-11) 11 (21.2%) 38 (29.0%) 0.67 (0.32-1.39) 0.90 (0.42-1.92) 
High(>11) 20 (38.5%) 42 (32.1%) 1.09 (0.59-2.01) 1.63 (0.85-3.14) 
Caffeine lifetime exposure, N (%)     
[weight (in mg) per 
day x years of 
exposure] 
Never/Low(< 10,600) 16 (30.7%) 45 (34.4%) 1 1 
Moderate (10,600 - 
16,400) 
20 (38.5%) 41 (31.3%) 1.26 (0.65-2.43) 0.81 (0.40-1.64) 
High (>16,400) 16 (30.7%) 45 (34.4%) 1.13 (0.56-2.25) 0.80 (0.38-1.67) 
Caffeine 3 years after diagnosis, N (%)     
 Never/Low (<513) 11 (21.2%) 50 (38.2%) 1 1 
Moderate(513-744) 20 (38.5%) 40 (30.5%) 1.56 (0.74-3.29) 1.40 (0.64-3.08) 
High(>744) 21 (40.4%) 41 (31.3%) 1.56 (0.75-3.24) 1.37 (0.65-2.87) 
*Cumulative levodopa-equivalent dose (LED) up to 4 years from diagnosis (mg lLevodopa-equivalent dose  x 
number of days of treatment x 10
-5
; one unit is equivalent to 70mg levodopa on average a day for 4 years). 
†Variables are adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS 
at diagnosis, and cCumulative lLevodopa dose 4 years from diagnosis). Abbreviations:  PIGD= postural 
instability and gait disorder.  
 
Table 3: Kaplan-Meier probabilities of developing motor fluctuations and dyskinesias after 
five years from dopaminergic treatment initiation, from levodopa initiation, and from 
diagnosis. 
Baseline for time measurement  Motor fluctuations  
 
Dyskinesias 
Any complication 
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     Starting dopaminergic treatment (N=183) 29.2% (21.5–38.8) 37.0% (28.5–47.1) 
     Starting levodopa treatment (N=160) 30.6% (22.6–40.7) 43.6% (33.7–54.9) 
     Diagnosis (N=-189) 23.42.8% (16.67–30.47) 29..36% (22.57–37.68) 
Severe complications 
19.8% (13.4–28.8) 
4.0% (1.5–10.4) 
     Starting dopaminergic treatment (N=183) 19.8% (13.4–28.8) 4.0% (1.5–10.4) 
95% confidence intervals are in parentheses. 
 
 
Motor fluctuations and dyskinesias 
23 patients (12.6%) had developed both fluctuations and dyskinesias by the time of data extraction, 
of whom 14 had developed dyskinesias first. 
 
 
DISCUSSION 
We have estimated that aAbout 30% of patients with PD developed motor fluctuations and about 
37% developed dyskinesias within five years of starting dopaminergic treatment. These were higher 
risks than described in two other community-based incidence cohorts that examined the 
development of dyskinesias. A Mayo Clinic series from the Mayo Clinic, between 1976 and 1990 
reported that 30% of patients developed dyskinesias of any severity were present in 30% of patients 
by five years of starting levodopa8 and in an incident cohort in Cambridge, UK,another study  fewer 
than 20% of patients developed dyskinesias five years from diagnosis.7 The reasons for these 
differences, between similar studies, are unclear. No previous community-based inception studies 
have reported the frequency of motor fluctuations. We found complications to be less common than 
several other studies, some of which were older and therefore used higher levodopa doses than are 
is used in current practice.4,18 Dyskinesias were more common in our cohort than motor fluctuations, 
similar to some studies15,28 but not others.16,12,18 Disabling dyskinesias were rare and, although the 
majority ofmost patients with motor fluctuations did have need changes in treatment, due to their 
development, only a small minorityvery few (4%) developed dyskinesias necessitating treatment 
Page 32 of 52European Journal of Neurology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
13 
 
changes in treatment (4% at 5 years). This is lower than one previous incident study in which 
reported that 17% of patients required treatment changes developed for dyskinesias that required 
treatment changes by within five years of levodopa treatment withinitiation levodopa.8 That study 
used patient records between 1976 and 1990 and the difference inlower incidence of severe 
dyskinesias in our study, could also be due to lower levodopa doses used in more recent prescribing 
practice.   
 
Levodopa exposure has consistently been reported as the strongest risk factor for the development 
of motor fluctuations and dyskinesias in observational studies,4,8,16 randomised trials of levodopa 
versus dopamine agonists29,30 and randomised trials of different levodopa doses.31 Previous studies 
have investigated several measures of levodopa exposure, including the initial average daily dose;7 
average daily LED;8 or levodopa dose at onset of dyskinesias (or end of study end in those without 
dyskinesias).12 Here we have compared cumulative both levodopa only and, levodopa-equivalent 
doses up to four years and early (within one year of diagnosis) commencement of levodopa. 
Although these variables were correlated, only cumulative levodopa dose was significantly 
associated with motor complications when they were entered into a multivariable model together. 
This suggests that there is little additional effect of non-levodopa dopaminergic treatments, which is 
similar to findings from a recent meta-analysis.32 It also suggests there is no absolute requirement to 
avoid early levodopa treatment in PD but, as others have suggested,12 it is important to use the 
smallest dose that adequately controls the patient’s symptoms throughout the course of PD. The 
fact that baseline motor severity (UPDRS) was not an independent risk factor for motor 
complications suggests that the association between cumulative levodopa dose and motor 
complications is not just due to worse disease severity with greater dopaminergic neuronal loss in 
those needing more levodopa.It can also be argued that levodopa dose is a proxy for disease 
severity, so that those with more aggressive disease are both more likely to get motor complications 
and to receive more levodopa. However, Oour data showed that baseline motor was not an 
Page 33 of 52 European Journal of Neurology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
14 
 
independent risk factor, although we may have been underpowered to detect this, which suggests 
this finding is not confounded by disease severity. This is in By contrast to This conflicts with  one 
large trial which found that both baseline disease severity and levodopa doses were associated with 
higher frequency of motor complications.12 However, eEvidence that levodopa increases risk of 
dyskinesias independently of disease severity also comes from randomised clinical trials, in which 
disease severity is randomly allocated to each arm, and those with higher doses of levodopa31 or 
levodopa and entacapone33 had higher incidence of dyskinesias. 
 
Many previous studies have shown a relationship betweenthat younger age at PD onset and 
developing motor complicationsis associated with more, in particular dyskinesias,9,10 and it was the 
most powerful predictor in a recent large trial.12 We found that age at diagnosis is an independent 
risk factor for developing motor fluctuations, but notdid not predict dyskinesias. This latter, similar 
to  finding supports results from another community- based incidence study that showed that age at 
baseline was not a risk factor for dyskinesias.7 It may be that, as a community-based incidence study, 
with proportionally few young-onset patients (4.4% under 50), there was insufficient power to 
detect an effect of age on dyskinesias.  
 
Duration between symptom onset and diagnosis was found to be an independent risk factor for 
developing dyskinesias but not motor fluctuations. This result was independent of baseline disease 
severity and levodopa dose so does not appear to be an effect of those presenting later being 
treated with higher doses of levodopa. This finding must be interpreted cautiously because it was a 
secondary analysis and the variable is subject to recall bias but it may suggests that patients that 
with more indolent onset of their PD symptoms may be at a higher risk of developing dyskinesias. 
 
The presence of tremor at diagnosis was associated with higher risk of both motor fluctuations and 
dyskinesias in the secondary analyses, which contrasts with a previous smaller study.34 Although this 
Page 34 of 52European Journal of Neurology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
15 
 
was consistent for both types of complications, the number without any tremor at baseline was 
small and thein this post-hoc analysis was not pre-specifiedsmall so this finding. This result, whilst 
novel and interesting, needs to berequires replicatedion in other studies.  
 
Female gender was an independent risk factor for both motor fluctuations and dyskinesias, as 
previous studies have also shown.12  The reasons for these gender differences in the development of 
motor complications are unclear. A possible explanation is that the lower average weight in females 
results in higher levodopa doses per body weight, and some previous studies found lower weight 
was a risk factor for dyskinesias.357,368 We did not, however, demonstrate an association with 
baseline weight but changes in weight after diagnosis may be more important in the development of 
complications. It has also been suggested that females have a reduced genetic protection from a 
dopamine receptor polymorphism,11 and hormonal differences may be important, with evidence 
from animal models of effects of oestrogen on the basal ganglia.3790  
 
Moderate lifetime caffeine exposure was associated with a reduced risk of developing motor 
fluctuations in the secondary multivariable analyses but there was no dose-response gradient and, 
given the large number of associations tested in the secondary analyses, it may well be a false 
positive. Nevertheless, Observational data from a clinical trial showed caffeine was associated with a 
lowered risk of dyskinesias20 and a clinical trial of another adenosine A2A antagonist, iIstradefylline 
reduced daily OFF time.21 Moderate lifetime caffeine exposure was associated with a reduced risk of 
developing motor fluctuations in the secondary multivariable analyses but there was no dose-
response gradient and, given the large number of associations tested in the secondary analyses, it 
may well be a false positive. Similarly, wWe did not find caffeine, smoking or alcohol exposure, 
either before or after diagnosis to be associated with lower risk of dyskinesias. This is in 
lineconsistent with a previous study which showed smoking was not associated with motor 
complications.14 However, we did not havelacked power to identify a small effects of these 
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exposures on motor complications; data was collected retrospectively for pre-diagnostic exposure; 
and there were very few current smokers in the cohort.  
 
The principal strengths of this study are its prospective design; the representative sample (attempts 
were made ito identify all patients in the community with a new diagnosis of PDparkinsonian 
syndrome); that diagnoses were regularly reviewed of diagnoses to achieve high improve diagnostic 
accuracy; that patients were reviewed clinicallyfrequent (at least yearly) clinical review to obtain 
data on motor complications; very high study retention; and careful statistical analyses. Additionally, 
cumulative levodopa doses were calculated up to 4 years rather than at complication onset. This is 
clearly better than comparing levodopa dose at onset of motor complications with levodopa dose at 
end of study in those without complications as this is confounded by difference in time. 
 
The study has several limitations. Firstly, study size, while not small in terms of previous studies of 
the development of motor complications, is not large enoughinsufficient to identify weak 
associations or investigate interactions. Secondly, average follow-up duration was only about five 
years, so better data may be obtained with longer follow-up. Thirdly, cumulative levodopa doses 
were calculated up to 4 years and not at complication onset. However, identifying a time-point for 
control comparisons would be difficult if this was done and thThis is clearly better than comparing 
levodopa dose at onset of motor complications with levodopa dose at end of study in those without 
complications as this is clearly confounded by difference in time. Fourthly, some inaccuracy in 
defining onset of complications is inevitable. Exact timing of onset of both dyskinesias and motor 
fluctuations was mostly subject to patient recall, although some patients’ dyskinesias were observed 
at clinic visits before they were noticed by the patients themselves, and were recorded as starting 
when seen. Thus the time to onset of dyskinesias may be overestimated. Assessment of severity was 
based on data about changes in therapy, which was derived from comprehensive clinical letter that 
invariably included reasons for treatment changes so we believe this was a reliable assessment. 
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Fourthly, the secondary analyses must be considered as exploratory as many variables were included 
examined and the associations identified may therefore betype I errors are possible false positives. 
Fifthly, data on caffeine, smoking and alcohol were partly retrospective, only average exposures 
were used, and we did not gather data on sources of caffeine other than tea and coffee.  
 
In conclusion, we are the first to describe the development of both motor fluctuations and 
dyskinesias in a representative, community-based, incident cohort of PD. We estimate that 29% and 
37% develop motor fluctuations and dyskinesias respectively after 5 years of dopaminergic 
treatment. Dyskinesias requiring treatment changes were rare (4% at 5 years), which is lower than 
previous estimates. Female sex, Hhigher cumulative levodopa dose, female sex, and tremor at 
diagnosis were independent risk factors for both motor complications; and moderate lifetime 
caffeine exposure and younger age withfor fewer motor fluctuations; and longer pre-diagnosis 
symptom duration for more dyskinesias. Further work with more patients with longer follow-up 
would be useful to obtainfor more detailed analysis of the risk factors associated with development 
of motor complications. Individual-patient-data meta-analysis of existing representative studies 
would be an efficient way to do this.  
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FIGURE LEGENDS 
 
Figure 1. Flow chart of patients included in the analysis and initiation of levodopa treatment. FU: Follow-Up. 
*Patients received only dopamine agonist or MAO-B inhibitors within 4 years of follow-up, except for 5 
patients who received treatment after 4 years of follow-up.  
 
Figure 2. Kaplan-Meier estimates of the probability that PD patients on a dopaminergic therapy will be free 
from (A) motor fluctuations and (B) dyskinesias.  In each graph, the blue line represents the development of 
any motor complication and the red represents the development of severe complications, i.e., those 
necessitating needing changes to treatment. 
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Title: Motor complications in an incident Parkinson’s disease cohort 
Manuscript ID: EJoN-15-0093 Author(s): Scott, Nicholas; Macleod, Angus; Counsell, Carl 
We would like to thank the reviewers for their helpful comments and include a detailed reply to 
individual comments, in red, below. 
Reviewer: 1 
COMMENTS TO AUTHOR(S) 
The present investigation drwas its major strength from its cohort based, incident-case methods. 
The theme is suitable for EJN and of clinical relevance, as it adresses one of the major concerns 
when manging tretment options for Parkinsons Disease Patients. There are, however, one point that 
deserve better explanation. The authors should be more precise regarding the type of dopaminergic 
tretament other than levo-dopa. How many patientes were on ropinierol, comt inhibitors, 
parmaipexeole and son on. 
Response to Reviewer: 1 
We have inserted the following explanation into the text (page 7, lines 4-7): 
 “The patients who received dopaminergic therapy in the first four years, but not levodopa, were 
mostly treated with ropinirole (33 patients), pramipexole (17 patients), selegiline (13 patients), 
COMT inhibitors (2 patients), rasagiline (1 patient), or ergot-derived dopamine agonists (2 patients).”  
 
Reviewer: 2 
COMMENTS TO AUTHOR(S) 
1. Did the authors collect information on the time between clinical onset of disease and 
diagnosis? 
 
This information was collected but not analysed. In response to the reviewer’s comment we have 
performed unadjusted and adjusted analysis of time between clinical onset and diagnosis. Longer 
duration between symptom onset and diagnosis was independently associated with risk of 
dyskinesias. The following changes have therefore been made: 
Inserted into the Abstract (p. 2, lines 22-23): “longer symptom duration”  
Inserted into the Methods (p.6, lines 9-10): “symptom duration prior to diagnosis,” 
Inserted into Results Tables 1 (p.8) and 2 (p.9).  
Inserted into Discussion (p.12, lines 15-20): “Duration between symptom onset and diagnosis was 
found to be an independent risk factor for developing dyskinesias but not motor fluctuations. This 
result was independent of baseline disease severity and levodopa dose so does not appear to be an 
effect of those presenting later being treated with higher doses of levodopa. This finding must be 
interpreted cautiously because it was a secondary analysis and the variable is subject to recall bias 
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but it may suggest that patients with more indolent onset of their PD symptoms may be at a higher 
risk of developing dyskinesias.” 
Inserted into Discussion (p.17, line 14): “and longer pre-diagnosis symptom duration for more 
dyskinesias” 
 
2. What was the percentage of change of diagnosis from baseline over follow up in this cohort? 
We have inserted the following comment into text to add this information Methods (p.4 line 13-14): 
“15% of patients with a latest diagnosis of PD had initially had an alternative diagnosis.” 
 
3. How reliable was the assessment of severe motor complication; onset of dyskinesias and 
motor fluctuations? 
We have added the following sentences into the Discussion (p.14 lines 7-13) to discuss the potential 
limitation of inaccuracies, particularly in identifying the timing of onset of these complications.  
“Thirdly, some inaccuracy in defining onset of complications is inevitable. Exact timing of onset of 
both dyskinesias and motor fluctuations was mostly subject to patient recall, although some 
patients’ dyskinesias were observed at clinic visits before they were noticed by the patients 
themselves, and were recorded as starting when seen. Thus the time to onset of dyskinesias may be 
overestimated. Assessment of severity was based on data about changes in therapy, which was 
derived from comprehensive clinical letter that invariably included reasons for treatment changes so 
we believe this was a reliable assessment.” 
 
4. It would be interesting to know why eight patients did not start levo-dopa or any dopaminergic 
agent. Were they different from the others? 
 
We have checked the case record for these patients and added the relevant data to the text. While 
doing this, we have discovered an error in the flow chart relating only to patients not included in the 
main analysis. We have updated figure 1 with the correct data. Those who were not treated were 
probably more likely to be tremor dominant in their presentation, but we have not made a formal 
comparison due to low numbers in this group. Their ages were similar. We have added the following 
reasons for patients not starting treatment into the Results section (p.6 , lines 22-25):  
“These patients (mean age 70.8) were not treated because they had mild disease with tremor 
dominance (N=3), had early dementia while motor symptoms were still mild (N=1), refused 
treatment (N=1), or did not tolerate levodopa (N=1).” 
 
 
5. What was the median duration of folow-up? 
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The median Follow-Up 60 months, IQR (48 months – 72 months). As this was very similar to the 
mean duration of follow-up (59 months, SD 22 months), which is stated in the text (page 7) we have 
not added the median follow-up to the manuscript. 
 
 6.      Did the authors distinguish in the analyses tremor dominant from akinetic phenotype with gait 
disturbances? This is of course different from presence of tremor at onset. 
We have added this data into the Results Tables 1 (p.8) and 2 (p.9). There was no significant effect of 
PD subtype on the risk of developing either motor fluctuations or dyskinesias.  
 
6. The authors should develop more the discussion on sex differences. 
 
We have expanded this section of the discussion, so that it now reads (p.13, lines 1-9):  
“Female gender was an independent risk factor for both motor fluctuations and dyskinesias, as 
previous studies have also shown.
12
 The reasons for gender differences in the development of motor 
complications are unclear. A possible xplanation is that lower average weight in females results in 
higher levodopa doses per body weight, and some previous studies found lower weight was a risk 
factor for dyskinesias.
35,36
 We did not, however, demonstrate an association with baseline weight 
but changes in weight after diagnosis may be more important in the development of complications. 
It has also been suggested that females have a reduced genetic protection from a dopamine 
receptor polymorphism,
11
 and hormonal differences may be important, with evidence from animal 
models of effects of oestrogen on the basal ganglia.
37
” 
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Table 1. Characteristics of patients who developed motor fluctuations 
 
Characteristics 
 
Patients with 
fluctuations  
N=39 
Patients 
without 
fluctuations 
N=144 
Unadjusted HR  
(95% CI) 
Adjusted HR* 
(95% CI) 
Age at diagnosis in years, median (IQR) 71 (64-74) 74 (69-80) 0.97 (0.94-0.99) 0.93 (0.90-0.97) 
Sex: Female, N (%) 23 (59.0%) 55 (38.2%) 1.80 (0.95-3.40) 2.41 (1.19-4.89) 
Weight at diagnosis in kg, median (IQR) 70 (64-84) 73 (62-83) 1.00 (0.98-1.03) 1.02 (0.99-1.05) 
Motor UPDRS at diagnosis, median (IQR) 26 (18-36) 24 (15-32) 1.02 (0.99-1.05) 1.00 (0.96-1.03) 
MMSE at diagnosis, median (IQR) 
(N=14 missing) 
29 (28-30) 29 (27-29) 1.17 (0.97-1.42) 1.13 (0.90-1.42) 
Tremor at diagnosis, N (%) 37 (95.0%) 123 (85.4%) 3.50 (0.84-14.58) 4.80 (1.12-20.72) 
Duration between symptom onset and diagnosis in 
years, median (IQR) 
1.17 (0.83—2.00) 1.17 (0.75-2.06) 0.93 (0.75-1.14) 0.89 (0.71-1.13) 
Started on Levodopa within 1 year from diagnosis, N 
(%) 
25 (64.1%) 103 (71.5%) 0.91 (0.47-1.76) 0.75 (0.29-1.92) 
Cumulative Levodopa dose 4 years from diagnosis, 
median (IQR) 
5.56 (1.40-7.60) 2.56 (0.63-4.38) 1.16 (1.04-1.30) 1.38 (1.19-1.60) 
Cumulative LED 4 years from diagnosis, median (IQR) 6.43 (3.37-7.60) 3.28 (1.88-5.08) 1.24 (1.08-1.46) 1.01 (0.76-1.36) 
PD Subtype, N (%)     
 PIGD 17 (43.6%) 75 (52.1%) 1 1 
Intermediate 6 (15.4%) 20 (13.9%) 1.33 (0.53-3.38) 2.00 (0.73-5.44) 
 Tremor dominant 16 (41.0%) 49 (34.0%) 1.31 (0.66-2.60) 1.59 (0.78-3.28) 
Smoking lifetime exposure, N (%)     
Pack years [cigarettes per 
day / 20 x number of years 
of exposure] 
Never 27 (69.2%) 78 (54.2%) 1 1 
Low (1-18) 6 (15.4%) 37 (47.4%) 0.59 (0.24-1.43) 0.79 (0.32-1.94) 
High (>18) 6 (15.4%) 29 (20.1%) 0.65 (0.27-1.57) 0.74 (0.30-1.85) 
Current smokers at diagnosis, N (%) 4 (10.3%) 8 (5.5%) 1.70 (0.60-4.78) 1.40 (0.50-4.00) 
Alcohol lifetime exposure, N (%)     
[units of alcohol per 
week x years of 
exposure] 
Never/Low(<40) 16 (41.0%) 45 (31.3%) 1 1 
Moderate(40-240) 12 (30.8%) 49 (34.0%) 0.73 (0.35-1.56) 0.79 (0.35-1.77) 
High(>240) 11 (28.2%) 50 (34.7%) 0.63 (0.29-1.36) 0.71 (0.30-1.70) 
Alcohol 3 years after diagnosis, N (%)     
 Never/Low(<1) 14 (35.9%) 58 (40.3%) 1 1 
Moderate(1-11) 11 (28.2%) 38 (26.4%) 1.19 (0.54-2.62) 1.70 (0.73-3.97) 
High(>11) 14 (35.9%) 48 (33.3%) 1.18 (0.56-2.47) 1.70 (0.79-3.60) 
Caffeine lifetime exposure, N (%)     
[weight (in mg) per 
day x years of 
exposure] 
Never/Low(< 10,600) 17 (43.6%) 44 (30.6%) 1 1 
Moderate (10,600 - 16,400) 13 (33.3%) 48 (33.3%) 0.53 (0.26-1.10) 0.34 (0.15-0.76) 
High (>16,400) 9 (23.1%) 52 (36.1%) 0.50 (0.22-1.12) 0.57 (0.24-1.40) 
Caffeine 3 years after diagnosis, N (%)     
 Never/Low (<513) 8 (20.5%) 53 (36.8%) 1 1 
Moderate(513-744) 18 (46.2%) 42 (29.2%) 1.59 (0.68-3.72) 1.58 (0.62-4.06) 
High(>744) 13 (33.3%) 49 (34.0%) 1.10 (0.46-2.67) 1.12 (0.44-2.89) 
*Variables adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor 
UPDRS at diagnosis, and cumulative levodopa dose 4). Abbreviation: PIGD= postural instability and 
gait disorder.  
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Table 2. Characteristics of patients who developed dyskinesias 
Characteristics 
 
Patients with 
dyskinesias  
N=52 
Patients without 
dyskinesias  
N=131 
Unadjusted HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
Age at diagnosis in years, median (IQR) 73 (70-78) 73 (65-80) 1.02 (0.99-1.05) 1.00 (0.97-1.03) 
Sex: Female, N (%) 29 (55.8%) 49 (37.4%) 1.79 (1.03-3.10) 2.51 (1.40-4.51) 
Weight at diagnosis in Kg, median (IQR) 67 (60-75) 75 (64-85) 0.97 (0.96-0.99) 0.99 (0.96-1.01) 
Motor UPDRS at diagnosis, median (IQR) 29 (19-37) 23 (15-32) 1.03 (1.01-1.06) 1.01 (0.98-1.04) 
MMSE at diagnosis, median (IQR) 
(N=14 missing) 
29 (28-29) 29 (27-29) 1.07 (0.94-1.23) 1.17 (1.00-1.36) 
Tremor at diagnosis, N (%) 49 (94.2%) 111 (84.7%) 2.82 (0.88-9.07) 3.68 (1.14-11.90) 
Duration between symptom onset and diagnosis 
in years, median (IQR) 
1.21 (0.71-2.15) 1.08 (0.75-2.00) 1.19 (1.05-1.35) 1.02 (1.01-1.03) 
Started on Levodopa within 1 year from 
diagnosis, N (%) 
41 (78.8%) 87 (66.4%) 2.20 (1.13-4.30) 1.55 (0.65-3.70) 
Cumulative Levodopa dose 4 years from 
diagnosis, median (IQR) 
4.48 (2.34-6.90) 2.37 (0.23-4.07) 1.19 (1.08-1.32) 1.23 (1.08-1.40) 
Cumulative LED 4 years from diagnosis, median 
(IQR) 
5.87 (3.06-7.10) 3.28 (1.73-4.99) 1.19 (1.06-1.35) 1.00 (0.75-1.30) 
PD Subtype, N (%)     
 PIGD 26 (50.0%) 66 (50.4%) 1 1 
Intermediate 6 (11.5%) 20 (15.3%) 0.76 (0.31-1.85) 1.23 (0.50-3.10) 
Tremor dominant 20 (38.5%) 45 (34.3%) 0.96 (0.54-1.73) 1.64 (0.86-3.12) 
Smoking lifetime exposure, N (%)     
Pack years [cigarettes 
per day / 20 x number 
of years of exposure] 
Never 30 (57.7%) 75 (57.3%) 1 1 
Low (1-18) 10 19.2%) 33 (25.2%) 0.95 (0.46-1.95) 1.08 (0.52-2.23) 
High (>18) 12 (23.1%) 23 (17.6%) 1.40 (0.71-2.73) 1.21 (0.60-2.44) 
Current smokers at diagnosis, N (%) 4 (8.0%) 8 (6.1%) 0.85 (0.30-2.37) 0.80 (0.30-2.30) 
Alcohol lifetime exposure, N (%)     
[units of alcohol per 
week x years of 
exposure] 
Never/Low(<40) 22 (42.3%) 39 (29.8%) 1 1 
Moderate(40-240) 14 (26.9%) 47 (35.9%) 0.53 (0.27-1.04) 0.63 (0.31-1.30) 
High(>240) 16 (30.8%) 45 (34.4%) 0.66 (0.35-1.30) 0.80 (0.38-1.68) 
Alcohol 3 years after diagnosis, N (%)     
 Never/Low(<1) 21 (40.4%) 51 (38.9%) 1 1 
Moderate(1-11) 11 (21.2%) 38 (29.0%) 0.67 (0.32-1.39) 0.90 (0.42-1.92) 
High(>11) 20 (38.5%) 42 (32.1%) 1.09 (0.59-2.01) 1.63 (0.85-3.14) 
Caffeine lifetime exposure, N (%)     
[weight (in mg) per 
day x years of 
exposure] 
Never/Low(< 10,600) 16 (30.7%) 45 (34.4%) 1 1 
Moderate (10,600 - 
16,400) 
20 (38.5%) 41 (31.3%) 1.26 (0.65-2.43) 0.81 (0.40-1.64) 
High (>16,400) 16 (30.7%) 45 (34.4%) 1.13 (0.56-2.25) 0.80 (0.38-1.67) 
Caffeine 3 years after diagnosis, N (%)     
 Never/Low (<513) 11 (21.2%) 50 (38.2%) 1 1 
Moderate(513-744) 20 (38.5%) 40 (30.5%) 1.56 (0.74-3.29) 1.40 (0.64-3.08) 
High(>744) 21 (40.4%) 41 (31.3%) 1.56 (0.75-3.24) 1.37 (0.65-2.87) 
*Variables are adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor 
UPDRS at diagnosis, and cumulative levodopa dose). Abbreviation: PIGD= postural instability and gait 
disorder.  
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Table 3: Kaplan-Meier probabilities of developing motor fluctuations and dyskinesias 
after five years from dopaminergic treatment initiation, from levodopa initiation, 
and from diagnosis. 
Baseline for time measurement  Motor fluctuations  
 
Dyskinesias 
Any complication 
     Starting dopaminergic treatment (N=183) 29.2% (21.5–38.8) 37.0% (28.5–47.1) 
     Starting levodopa treatment (N=160) 30.6% (22.6–40.7) 43.6% (33.7–54.9) 
     Diagnosis (N=189) 22.8% (16.7–30.7) 29.6% (22.7–37.8) 
Severe complications 
     Starting dopaminergic treatment (N=183) 19.8% (13.4–28.8) 4.0% (1.5–10.4) 
95% confidence intervals are in parentheses. 
 
Page 50 of 52European Journal of Neurology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 2  
203x295mm (300 x 300 DPI)  
 
 
Page 51 of 52 European Journal of Neurology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 52 of 52European Journal of Neurology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
